Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14656440 | 0.95 | ALDH1A1 (0.52) | ALDH1A1HPGDFDPSKDM4EHTR1A | |
| SCHEMBL14656287 | 0.93 | ALDH1A1 (0.50) | ALDH1A1HPGDFDPSKDM4EHTR1A | |
| SCHEMBL14656528 | 0.93 | ALDH1A1 (0.50) | ALDH1A1HPGDFDPSKDM4EHTR1A | |
| SCHEMBL14656661 | 0.93 | ALDH1A1 (0.50) | ALDH1A1HPGDFDPSKDM4EHTR1A | |
| SCHEMBL14656337 | 0.93 | ALDH1A1 (0.50) | ALDH1A1HPGDFDPSKDM4EHTR1A | |
| SCHEMBL14656566 | 0.93 | ALDH1A1 (0.50) | ALDH1A1HPGDFDPSKDM4EHTR1A | |
| SCHEMBL14656567 | 0.93 | ALDH1A1 (0.50) | ALDH1A1HPGDFDPSKDM4EHTR1A | |
| SCHEMBL14656484 | 0.93 | ALDH1A1 (0.50) | ALDH1A1HPGDFDPSKDM4EHTR1A | |
| SCHEMBL14656506 | 0.93 | ALDH1A1 (0.50) | ALDH1A1HPGDFDPSKDM4EHTR1A | |
| SCHEMBL14656533 | 0.93 | ALDH1A1 (0.50) | ALDH1A1HPGDFDPSKDM4EHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906915-B2 | Compounds, compositions, and methods for controlling biofilms | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-12-09 | — | — | US | claimed |
| US-20130029981-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-01-31 | — | — | US | claimed |
| US-8906915-B2 | Compounds, compositions, and methods for controlling biofilms | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-12-09 | — | — | US | disclosed |
| US-8906915-B2 | Compounds, compositions, and methods for controlling biofilms | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-12-09 | — | — | US | disclosed |
| US-8906915-B2 | Compounds, compositions, and methods for controlling biofilms | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-12-09 | — | — | US | disclosed |
| US-20130029981-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-01-31 | — | — | US | disclosed |
| US-20130029981-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-01-31 | — | — | US | disclosed |
| US-20130029981-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029981-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | AZI2, NOD1, AADAC | ALDH1A1 373/4885HPGD 620/4885FDPS 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.